Clinical Trial

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-06-30.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-21
Trial Details
NCT Number NCT02487693
Lead Sponsor The First People's Hospital of Changzhou
Conditions Ovarian Carcinoma
Enrollment 50 participants
Start Date 2015-07
Primary Completion 2038-06 (estimated)
Study Completion 2040-06 (estimated)
Updated on ClinicalTrials.gov 2016-02-23